Abstract 2282P
Background
The immune system can eliminate malignancy by identifying antigenic peptide epitope presented by neoplastically transformed cells. Immune cells recognize abnormal glycosylation on cancer cells, and this recognition often leads to an inhibitory immune process. We designed a biomedical study to evaluate the role of tissue glycan in predicting immunotherapy response in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
Methods
Thirty-two patients with intermediate/poor risk RCC and advanced HCC (eight respondents and eight non-respondents each) who had received first line immunotherapy-based therapy were identified. The overall survival for RCC and HCC non-respondent cohort was 27.9 months and 8 months respectively but was immature for the respondent cohort. Response criteria to immunotherapy was decided based on the immune related response criteria (iRECIST) where good response is defined as complete or partial response while poor respondent was defined as progression of disease with median survival shorter than reported. Next, we compare the relative abundance and spatial distribution of the glycans in the responder versus non-responder tissue sections given regional characterizations within the tissues. This helps points out the distinct glycans between the responder versus non-responder tissue sections that could serve as potential biomarkers which can then be used in future diagnostic and/or therapeutic intervention. We used the MALDI analysis by rapifleX.
Results
MALDI imaging of HCC and RCC responder versus non-responder tissue section was successfully demonstrated. There was distinct responder versus non responder glycan markers demonstrated by unsupervised segmentation analysis, showing specific layers of glycan organization in the different tissue regions. There are several glycan peaks showing distinctive expression between respondent versus non respondent patients. PCA showed distinguishable variances across each annotated structures derived from segmentation analysis.
Conclusions
Distinct glycan profile markers were observed between both responder and non-responder cohort showing specific layers of glycan organization in the different tissue regions.
Clinical trial identification
NHG DSRB Ref: 2021/01072
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NMC CG program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2284P - Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Presenter: Andreas Ackermann
Session: Poster session 08
2285P - Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls
Presenter: Pedro Cruz
Session: Poster session 08
2286P - COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
Presenter: Ha Mo Linh Le
Session: Poster session 08
2288P - Recolony-treating solid tumors with a bacteria-based approach
Presenter: Egle Katkeviciute
Session: Poster session 08
2289P - Determining anti-cancer efficacy of a reversible LSD1 inhibitor, EXS74539, in primary AML tissues with limited thrombocytopenic effects
Presenter: Christophe Boudesco
Session: Poster session 08
2291P - WU-NK-101, best in class memory-NK cell, has key features vital for adoptive cell therapy (ACT) in solid tumors (ST)
Presenter: John Muth
Session: Poster session 08
2292P - Prevalence of druggable EGFR genomic alterations in solid tumours other than lung cancer
Presenter: Tomohiro Kondo
Session: Poster session 08
2293P - Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
Presenter: Carlotta Catozzi
Session: Poster session 08
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08